Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Global Blood nets $112.8mm through public offering

Executive Summary

Global Blood Therapeutics Inc. (developing treatments for blood-based diseases) netted $112.8mm through a public sale of 6.4mm common shares at $18.75. Proceeds will fund development activities, including completion of Phase I/II trials with GBT440 for sickle cell disease; planned trials for GBT440 for idiopathic pulmonary fibrosis and other hypoxemic pulmonary disorders; and initiation of development of GBT018713 for the treatment of hereditary angioedema.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies